Boehringer Ingelheim Drug Patent Portfolio
Boehringer Ingelheim owns 26 orange book drugs protected by 186 US patents with Aggrenox having the least patent protection, holding only 1 patent. And Spiriva Respimat with maximum patent protection, holding 39 patents. Given below is the complete list of Boehringer Ingelheim's drugs and the patents protecting them.
1. Aggrenox
Aggrenox is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6015577 | Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation |
18 Jan, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aggrenox's drug page
2. Aptivus
Aptivus is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6147095
(Pediatric)
| Method for improving the pharmacokinetics of tipranavir |
29 Apr, 2020
(4 years ago)
| Expired |
| US5852195
(Pediatric)
| Pyranone compounds useful to treat retroviral infections |
22 Dec, 2019
(4 years ago)
| Expired |
| US6147095 | Method for improving the pharmacokinetics of tipranavir |
29 Oct, 2019
(4 years ago)
| Expired |
| US5852195 | Pyranone compounds useful to treat retroviral infections |
22 Jun, 2019
(5 years ago)
| Expired |
| US6231887
(Pediatric)
| Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
27 Jan, 2019
(5 years ago)
| Expired |
| US6231887 | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation |
27 Jul, 2018
(6 years ago)
| Expired |
| US6169181
(Pediatric)
| Compounds useful to treat retroviral infections |
06 Nov, 2014
(9 years ago)
| Expired |
| US6169181 | Compounds useful to treat retroviral infections |
06 May, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aptivus's drug page
3. Atrovent Hfa
Atrovent Hfa is protected by 5 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8474447 | Inhaler device |
17 Jan, 2030
(5 years from now)
| Active |
| US6739333 | Stainless steel canister for propellant-driven metering aerosols |
26 May, 2020
(4 years ago)
| Expired |
| US6983743 | Stainless steel canister for propellant-driven metering aerosols |
26 May, 2020
(4 years ago)
| Expired |
| US5683677 | Medicinal aerosol formulations |
04 Nov, 2014
(9 years ago)
| Expired |
| US5676930 | Stabilized medicinal aerosol solution formulations |
14 Oct, 2014
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Atrovent Hfa's drug page
4. Combivent
Combivent is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5603918 | Aerosol composition of a salt of ipratropium and a salt of albuterol |
09 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivent's drug page
5. Combivent Respimat
Combivent Respimat is protected by 24 patents, out of which 19 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(6 years from now)
| Active |
| US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
| US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
| US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(2 years from now)
| Active |
| US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(8 months from now)
| Active |
| US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(24 days ago)
| Expired |
| US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
| US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
| US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
| US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| US6149054 | Mechanical counter for a metering apparatus |
19 Dec, 2016
(7 years ago)
| Expired |
| US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(7 years ago)
| Expired |
| US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US6176442 | Device for mounting a component exposed to a pressurized fluid |
04 Oct, 2016
(7 years ago)
| Expired |
| US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
| US5662271 | Atomizing devices and methods |
02 Sep, 2014
(10 years ago)
| Expired |
| US5472143 | Atomising nozzle and filter and spray generation device |
29 Sep, 2013
(10 years ago)
| Expired |
| US5911851 | Atomizing nozzle and filter and spray generating device |
29 Sep, 2013
(10 years ago)
| Expired |
| US6007676 | Atomizing nozzle and filter and spray generating device |
29 Sep, 2013
(10 years ago)
| Expired |
| US6503362 | Atomizing nozzle an filter and spray generating device |
29 Sep, 2013
(10 years ago)
| Expired |
| US5497944 | Atomising devices and methods |
12 Mar, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Combivent Respimat's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Gilotrif
Gilotrif is protected by 11 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10004743
(Pediatric)
| Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
05 Jan, 2031
(6 years from now)
| Active |
| US10004743 | Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient |
05 Jul, 2030
(5 years from now)
| Active |
| US8545884
(Pediatric)
| Solid pharmaceutical formulations comprising BIBW 2992 |
19 Jun, 2030
(5 years from now)
| Active |
| US8426586
(Pediatric)
| Process for preparing amino crotonyl compounds |
10 Apr, 2030
(5 years from now)
| Active |
| US8545884 | Solid pharmaceutical formulations comprising BIBW 2992 |
19 Dec, 2029
(5 years from now)
| Active |
| US8426586 | Process for preparing amino crotonyl compounds |
10 Oct, 2029
(5 years from now)
| Active |
| US9539258
(Pediatric)
| Quinazoline derivatives for the treatment of cancer diseases |
09 May, 2027
(2 years from now)
| Active |
| US9539258 | Quinazoline derivatives for the treatment of cancer diseases |
09 Nov, 2026
(2 years from now)
| Active |
| USRE43431
(Pediatric)
| Quinazoline derivatives and pharmaceutical compositions containing them |
13 Jul, 2026
(1 year, 9 months from now)
| Active |
| USRE43431 | Quinazoline derivatives and pharmaceutical compositions containing them |
13 Jan, 2026
(1 year, 3 months from now)
| Active |
| US6251912 | Substituted quinazoline derivatives |
29 Jul, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Gilotrif's drug page
7. Glyxambi
Glyxambi is protected by 29 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
| US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US10406172 | Pharmaceutical composition, methods for treating and uses thereof |
15 Jun, 2030
(5 years from now)
| Active |
| US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
| US8551957
(Pediatric)
| Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Apr, 2030
(5 years from now)
| Active |
| US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Oct, 2029
(5 years from now)
| Active |
| US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
| US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
| US11033552
(Pediatric)
| DPP IV inhibitor formulations |
04 Nov, 2027
(3 years from now)
| Active |
| US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(3 years from now)
| Active |
| US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(3 years from now)
| Active |
| US11033552 | DPP IV inhibitor formulations |
04 May, 2027
(2 years from now)
| Active |
| US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
| US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 8 months from now)
| Active |
| US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(1 year, 2 months from now)
| Active |
| US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(1 year, 1 month from now)
| Active |
| US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(7 months from now)
| Active |
| US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glyxambi's drug page
8. Jardiance
Jardiance is protected by 18 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9949998
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
11 Dec, 2034
(10 years from now)
| Active |
| US9949997
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
17 Nov, 2034
(10 years from now)
| Active |
| US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
| US9949997 | Pharmaceutical composition, methods for treating and uses thereof |
17 May, 2034
(9 years from now)
| Active |
| US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11666590 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11813275 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US10406172 | Pharmaceutical composition, methods for treating and uses thereof |
15 Jun, 2030
(5 years from now)
| Active |
| US8551957
(Pediatric)
| Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Apr, 2030
(5 years from now)
| Active |
| US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Oct, 2029
(5 years from now)
| Active |
| US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
| US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
| US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(3 years from now)
| Active |
| US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jardiance's drug page
9. Jentadueto
Jentadueto is protected by 24 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8846695
(Pediatric)
| Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Dec, 2030
(6 years from now)
| Active |
| US9155705
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 Nov, 2030
(6 years from now)
| Active |
| US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
| US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 May, 2030
(5 years from now)
| Active |
| US11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
10 Apr, 2030
(5 years from now)
| Active |
| US10022379
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(5 years from now)
| Active |
| US10973827
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(5 years from now)
| Active |
| US9415016
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(5 years from now)
| Active |
| US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
| US10973827 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
| US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
| US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(3 years from now)
| Active |
| US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 8 months from now)
| Active |
| US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(1 year, 2 months from now)
| Active |
| US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(1 year, 1 month from now)
| Active |
| US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(7 months from now)
| Active |
| US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jentadueto's drug page
10. Jentadueto Xr
Jentadueto Xr is protected by 27 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9555001
(Pediatric)
| Pharmaceutical composition and uses thereof |
06 Sep, 2033
(8 years from now)
| Active |
| US9555001 | Pharmaceutical composition and uses thereof |
06 Mar, 2033
(8 years from now)
| Active |
| US9155705
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 Nov, 2030
(6 years from now)
| Active |
| US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
| US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 May, 2030
(5 years from now)
| Active |
| US11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
10 Apr, 2030
(5 years from now)
| Active |
| US10022379
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(5 years from now)
| Active |
| US9415016
(Pediatric)
| DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Oct, 2029
(5 years from now)
| Active |
| US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
| US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
| US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(3 years from now)
| Active |
| US9173859
(Pediatric)
| Uses of DPP IV inhibitors |
04 Nov, 2027
(3 years from now)
| Active |
| US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 8 months from now)
| Active |
| US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(1 year, 2 months from now)
| Active |
| US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(1 year, 1 month from now)
| Active |
| US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(7 months from now)
| Active |
| US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
| US6340475 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
| US6635280 | Extending the duration of drug release within the stomach during the fed mode |
19 Sep, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jentadueto Xr's drug page
11. Micardis
Micardis is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8003679 | Use of inhibitors of the renin-angiotensin system |
06 Oct, 2022
(1 year, 11 months ago)
| Expired |
| US7998953 | Use of inhibitors of the renin-angiotensin system |
06 Jun, 2020
(4 years ago)
| Expired |
| US6358986 | Polymorphs of telmisartan |
10 Jan, 2020
(4 years ago)
| Expired |
| US5591762 | Benzimidazoles useful as angiotensin-11 antagonists |
07 Jan, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micardis's drug page
12. Micardis Hct
Micardis Hct is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6358986 | Polymorphs of telmisartan |
10 Jan, 2020
(4 years ago)
| Expired |
| US5591762 | Benzimidazoles useful as angiotensin-11 antagonists |
07 Jan, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Micardis Hct's drug page
13. Mirapex
Mirapex is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6001861 | Use of pramipexole in the treatment of restless legs syndrome |
16 Jan, 2018
(6 years ago)
| Expired |
| US6194445 | Use of pramipexole in the treatment of restless legs syndrome |
16 Jan, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirapex's drug page
14. Mirapex Er
Mirapex Er is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8679533 | Pramipexole once-daily dosage form |
08 Sep, 2029
(4 years from now)
| Active |
| US7695734 | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
26 Apr, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirapex Er's drug page
15. Ofev
Ofev is protected by 10 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9907756
(Pediatric)
| Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
07 Dec, 2029
(5 years from now)
| Active |
| US10105323
(Pediatric)
| Pharmaceutical dosage form for immediate release of an indolinone derivative |
04 Dec, 2029
(5 years from now)
| Active |
| US9907756 | Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative |
07 Jun, 2029
(4 years from now)
| Active |
| US10105323 | Pharmaceutical dosage form for immediate release of an indolinone derivative |
04 Jun, 2029
(4 years from now)
| Active |
| US10154990
(Pediatric)
| Medicaments for the treatment or prevention of fibrotic diseases |
08 Jul, 2026
(1 year, 9 months from now)
| Active |
| US6762180
(Pediatric)
| Substituted indolines which inhibit receptor tyrosine kinases |
01 Apr, 2026
(1 year, 6 months from now)
| Active |
| US10154990 | Medicaments for the treatment or prevention of fibrotic diseases |
08 Jan, 2026
(1 year, 3 months from now)
| Active |
| US6762180 | Substituted indolines which inhibit receptor tyrosine kinases |
01 Oct, 2025
(1 year, 11 days from now)
| Active |
| US7989474 | Use of Lck inhibitors for treatment of immunologic diseases |
06 Apr, 2024
(5 months ago)
| Expired |
| US7119093 | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
21 Feb, 2024
(6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ofev's drug page
16. Pradaxa
Pradaxa is protected by 11 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9034822
(Pediatric)
| Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
20 Jul, 2031
(6 years from now)
| Active |
| US9034822 | Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds |
20 Jan, 2031
(6 years from now)
| Active |
| US7866474
(Pediatric)
| Film container |
02 Mar, 2028
(3 years from now)
| Active |
| US7866474 | Film container |
31 Aug, 2027
(2 years from now)
| Active |
| US7932273
(Pediatric)
| 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
07 Mar, 2026
(1 year, 5 months from now)
| Active |
| US7932273 | 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament |
07 Sep, 2025
(11 months from now)
| Active |
| US9925174
(Pediatric)
| Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
14 Dec, 2023
(9 months ago)
| Expired |
| US9925174 | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof |
14 Jun, 2023
(1 year, 3 months ago)
| Expired |
| US6087380
(Pediatric)
| Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
28 Jun, 2022
(2 years ago)
| Expired |
| US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
28 Dec, 2021
(2 years ago)
| Expired |
| US6087380 | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
18 Feb, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pradaxa's drug page
17. Spiriva
Spiriva is protected by 20 patents, out of which 15 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9010323 | Inhaler and sieve for an inhaler |
19 Apr, 2030
(5 years from now)
| Active |
| US7694676
(Pediatric)
| Dry powder inhaler |
12 Sep, 2027
(2 years from now)
| Active |
| US7694676 | Dry powder inhaler |
12 Mar, 2027
(2 years from now)
| Active |
| US8022082
(Pediatric)
| Method for the administration of an anticholinergic by inhalation |
19 Jul, 2026
(1 year, 9 months from now)
| Active |
| US8022082 | Method for the administration of an anticholinergic by inhalation |
19 Jan, 2026
(1 year, 3 months from now)
| Active |
| US7070800
(Pediatric)
| Inhalable powder containing tiotropium |
22 Jul, 2022
(2 years ago)
| Expired |
| USRE38912
(Pediatric)
| Process for preparing powder formulations |
11 Apr, 2022
(2 years ago)
| Expired |
| US6777423
(Pediatric)
| Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Mar, 2022
(2 years ago)
| Expired |
| US6908928
(Pediatric)
| Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Mar, 2022
(2 years ago)
| Expired |
| US7309707
(Pediatric)
| Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Mar, 2022
(2 years ago)
| Expired |
| US7642268
(Pediatric)
| Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Mar, 2022
(2 years ago)
| Expired |
| US7070800 | Inhalable powder containing tiotropium |
22 Jan, 2022
(2 years ago)
| Expired |
| USRE38912 | Process for preparing powder formulations |
11 Oct, 2021
(2 years ago)
| Expired |
| US6777423 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Sep, 2021
(2 years ago)
| Expired |
| US6908928 | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
24 Sep, 2021
(2 years ago)
| Expired |
| US7309707 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Sep, 2021
(2 years ago)
| Expired |
| US7642268 | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
24 Sep, 2021
(2 years ago)
| Expired |
| USRE39820
(Pediatric)
| Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jul, 2018
(6 years ago)
| Expired |
| USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jan, 2018
(6 years ago)
| Expired |
| US5478578 | Powders for inhalation |
26 Dec, 2012
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spiriva's drug page
18. Spiriva Respimat
Spiriva Respimat is protected by 39 patents, out of which 28 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8733341
(Pediatric)
| Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Apr, 2031
(6 years from now)
| Active |
| US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(6 years from now)
| Active |
| US7837235
(Pediatric)
| Device for clamping a fluidic component |
13 Sep, 2028
(3 years from now)
| Active |
| US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
| US9027967
(Pediatric)
| Device for clamping a fluidic component |
01 Oct, 2027
(3 years from now)
| Active |
| US7396341
(Pediatric)
| Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Apr, 2027
(2 years from now)
| Active |
| US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
| US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(2 years from now)
| Active |
| US7896264
(Pediatric)
| Microstructured high pressure nozzle with built-in filter function |
26 Nov, 2025
(1 year, 2 months from now)
| Active |
| US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(8 months from now)
| Active |
| US7284474
(Pediatric)
| Piston-pumping system having o-ring seal properties |
26 Feb, 2025
(5 months from now)
| Active |
| US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(24 days ago)
| Expired |
| US7988001
(Pediatric)
| Container provided with a pressure equalization opening |
04 Feb, 2022
(2 years ago)
| Expired |
| US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
| US6988496
(Pediatric)
| Cartridge for a liquid |
23 Aug, 2020
(4 years ago)
| Expired |
| US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
| US7802568
(Pediatric)
| Cartridge for a liquid |
26 Aug, 2019
(5 years ago)
| Expired |
| US6846413
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
| US6977042
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
| US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
| US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| USRE39820
(Pediatric)
| Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jul, 2018
(6 years ago)
| Expired |
| USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jan, 2018
(6 years ago)
| Expired |
| US6149054
(Pediatric)
| Mechanical counter for a metering apparatus |
16 Jun, 2017
(7 years ago)
| Expired |
| US6453795
(Pediatric)
| Locking mechanism for a spring-actuated device |
05 Jun, 2017
(7 years ago)
| Expired |
| US5964416
(Pediatric)
| Device for producing high pressure in a fluid in miniature |
04 Apr, 2017
(7 years ago)
| Expired |
| US6726124
(Pediatric)
| Device for producing high pressure in a fluid in miniature |
04 Apr, 2017
(7 years ago)
| Expired |
| US7104470
(Pediatric)
| Device for producing high pressure in a fluid in miniature |
04 Apr, 2017
(7 years ago)
| Expired |
| US6149054 | Mechanical counter for a metering apparatus |
16 Dec, 2016
(7 years ago)
| Expired |
| US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(7 years ago)
| Expired |
| US6176442
(Pediatric)
| Device for mounting a component exposed to a pressurized fluid |
01 Dec, 2016
(7 years ago)
| Expired |
| US7246615
(Pediatric)
| Atomising nozzle and filter and spray generating device |
01 Dec, 2016
(7 years ago)
| Expired |
| US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US6176242 | Method of treating manic depression by brain infusion |
31 May, 2016
(8 years ago)
| Expired |
| US6176442 | Device for mounting a component exposed to a pressurized fluid |
31 May, 2016
(8 years ago)
| Expired |
| US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Spiriva Respimat's drug page
19. Stiolto Respimat
Stiolto Respimat is protected by 34 patents, out of which 23 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(6 years from now)
| Active |
| US7837235
(Pediatric)
| Device for clamping a fluidic component |
13 Sep, 2028
(3 years from now)
| Active |
| US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
| US7396341
(Pediatric)
| Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Apr, 2027
(2 years from now)
| Active |
| US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
| US7727984 | Medicaments for the treatment of chronic obstructive pulmonary disease |
19 Jan, 2027
(2 years from now)
| Active |
| US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(2 years from now)
| Active |
| US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(8 months from now)
| Active |
| US7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(7 months from now)
| Active |
| US8034809 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(7 months from now)
| Active |
| US7284474
(Pediatric)
| Piston-pumping system having o-ring seal properties |
26 Feb, 2025
(5 months from now)
| Active |
| US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(24 days ago)
| Expired |
| US7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease |
07 Dec, 2023
(9 months ago)
| Expired |
| US7491719 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
10 Nov, 2023
(10 months ago)
| Expired |
| US7786111 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(10 months ago)
| Expired |
| US8044046 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(10 months ago)
| Expired |
| US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
| US6988496
(Pediatric)
| Cartridge for a liquid |
23 Aug, 2020
(4 years ago)
| Expired |
| US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
| US7802568
(Pediatric)
| Cartridge for a liquid |
26 Aug, 2019
(5 years ago)
| Expired |
| US6846413
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
| US6977042
(Pediatric)
| Microstructured filter |
28 Feb, 2019
(5 years ago)
| Expired |
| US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
| US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| USRE39820 | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
30 Jan, 2018
(6 years ago)
| Expired |
| US6149054
(Pediatric)
| Mechanical counter for a metering apparatus |
19 Jun, 2017
(7 years ago)
| Expired |
| US6149054 | Mechanical counter for a metering apparatus |
19 Dec, 2016
(7 years ago)
| Expired |
| US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(7 years ago)
| Expired |
| US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US6176442 | Device for mounting a component exposed to a pressurized fluid |
04 Oct, 2016
(7 years ago)
| Expired |
| US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Stiolto Respimat's drug page
20. Striverdi Respimat
Striverdi Respimat is protected by 25 patents, out of which 17 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8733341 | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
16 Oct, 2030
(6 years from now)
| Active |
| US7837235 | Device for clamping a fluidic component |
13 Mar, 2028
(3 years from now)
| Active |
| US9027967 | Device for clamping a fluidic component |
31 Mar, 2027
(2 years from now)
| Active |
| US7727984 | Medicaments for the treatment of chronic obstructive pulmonary disease |
19 Jan, 2027
(2 years from now)
| Active |
| US7396341 | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
10 Oct, 2026
(2 years from now)
| Active |
| US7896264 | Microstructured high pressure nozzle with built-in filter function |
26 May, 2025
(8 months from now)
| Active |
| US7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(7 months from now)
| Active |
| US8034809 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
12 May, 2025
(7 months from now)
| Active |
| US7284474 | Piston-pumping system having o-ring seal properties |
26 Aug, 2024
(24 days ago)
| Expired |
| US7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease |
07 Dec, 2023
(9 months ago)
| Expired |
| US7491719 | Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments |
10 Nov, 2023
(10 months ago)
| Expired |
| US7786111 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(10 months ago)
| Expired |
| US8044046 | Medicaments for the treatment of chronic obstructive pulmonary disease |
10 Nov, 2023
(10 months ago)
| Expired |
| US7988001 | Container provided with a pressure equalization opening |
04 Aug, 2021
(3 years ago)
| Expired |
| US6988496 | Cartridge for a liquid |
23 Feb, 2020
(4 years ago)
| Expired |
| US7802568 | Cartridge for a liquid |
26 Feb, 2019
(5 years ago)
| Expired |
| US6846413 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| US6977042 | Microstructured filter |
28 Aug, 2018
(6 years ago)
| Expired |
| US6149054 | Mechanical counter for a metering apparatus |
19 Dec, 2016
(7 years ago)
| Expired |
| US6453795 | Locking mechanism for a spring-actuated device |
05 Dec, 2016
(7 years ago)
| Expired |
| US5964416 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US6176442 | Device for mounting a component exposed to a pressurized fluid |
04 Oct, 2016
(7 years ago)
| Expired |
| US6726124 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US7104470 | Device for producing high pressure in a fluid in miniature |
04 Oct, 2016
(7 years ago)
| Expired |
| US7246615 | Atomising nozzle and filter and spray generating device |
31 May, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Striverdi Respimat's drug page
21. Synjardy
Synjardy is protected by 14 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9949997
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
17 Nov, 2034
(10 years from now)
| Active |
| US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US9949997 | Pharmaceutical composition, methods for treating and uses thereof |
17 May, 2034
(9 years from now)
| Active |
| US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11813275 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US10610489
(Pediatric)
| Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
30 Mar, 2031
(6 years from now)
| Active |
| US10610489 | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
30 Sep, 2030
(6 years from now)
| Active |
| US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
| US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
| US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(3 years from now)
| Active |
| US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synjardy's drug page
22. Synjardy Xr
Synjardy Xr is protected by 17 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9949998
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
11 Dec, 2034
(10 years from now)
| Active |
| US9949997
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
17 Nov, 2034
(10 years from now)
| Active |
| US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
| US9949997 | Pharmaceutical composition, methods for treating and uses thereof |
17 May, 2034
(9 years from now)
| Active |
| US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11813275 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US10596120
(Pediatric)
| Pharmaceutical compositions |
07 Sep, 2032
(7 years from now)
| Active |
| US10596120 | Pharmaceutical compositions |
07 Mar, 2032
(7 years from now)
| Active |
| US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
| US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
| US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(3 years from now)
| Active |
| US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Synjardy Xr's drug page
23. Tradjenta
Tradjenta is protected by 24 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8853156
(Pediatric)
| Treatment for diabetes in patients inappropriate for metformin therapy |
05 Sep, 2031
(6 years from now)
| Active |
| US8853156 | Treatment for diabetes in patients inappropriate for metformin therapy |
05 Mar, 2031
(6 years from now)
| Active |
| US8846695
(Pediatric)
| Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Dec, 2030
(6 years from now)
| Active |
| US8846695 | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
04 Jun, 2030
(5 years from now)
| Active |
| US11911388 | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug |
10 Apr, 2030
(5 years from now)
| Active |
| US10034877
(Pediatric)
| Treatment for diabetes in patients inappropriate for metformin therapy |
05 Feb, 2030
(5 years from now)
| Active |
| US9486526
(Pediatric)
| Treatment for diabetes in patients inappropriate for metformin therapy |
05 Feb, 2030
(5 years from now)
| Active |
| US10034877 | Treatment for diabetes in patients inappropriate for metformin therapy |
05 Aug, 2029
(4 years from now)
| Active |
| US9486526 | Treatment for diabetes in patients inappropriate for metformin therapy |
05 Aug, 2029
(4 years from now)
| Active |
| US11033552
(Pediatric)
| DPP IV inhibitor formulations |
04 Nov, 2027
(3 years from now)
| Active |
| US8673927
(Pediatric)
| Uses of DPP-IV inhibitors |
04 Nov, 2027
(3 years from now)
| Active |
| US11033552 | DPP IV inhibitor formulations |
04 May, 2027
(2 years from now)
| Active |
| US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 8 months from now)
| Active |
| US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(1 year, 2 months from now)
| Active |
| US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(1 year, 1 month from now)
| Active |
| US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(7 months from now)
| Active |
| US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US6890898 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7078381 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US7459428 | Method of regulating glucose metabolism, and reagents related thereto |
02 Feb, 2019
(5 years ago)
| Expired |
| US6303661 | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
24 Apr, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tradjenta's drug page
24. Trijardy Xr
Trijardy Xr is protected by 28 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9949998
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
11 Dec, 2034
(10 years from now)
| Active |
| US10258637
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US11090323
(Pediatric)
| Pharmaceutical composition, methods for treating and uses thereof |
03 Oct, 2034
(10 years from now)
| Active |
| US9949998 | Pharmaceutical composition, methods for treating and uses thereof |
11 Jun, 2034
(9 years from now)
| Active |
| US10258637 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11090323 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US11833166 | Pharmaceutical composition, methods for treating and uses thereof |
03 Apr, 2034
(9 years from now)
| Active |
| US10596120 | Pharmaceutical compositions |
07 Mar, 2032
(7 years from now)
| Active |
| US11564886 | Pharmaceutical compositions |
07 Mar, 2032
(7 years from now)
| Active |
| US10406172 | Pharmaceutical composition, methods for treating and uses thereof |
15 Jun, 2030
(5 years from now)
| Active |
| US9155705 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
21 May, 2030
(5 years from now)
| Active |
| US8551957
(Pediatric)
| Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Apr, 2030
(5 years from now)
| Active |
| US8551957 | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
14 Oct, 2029
(5 years from now)
| Active |
| US10022379 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
| US9415016 | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
02 Apr, 2029
(4 years from now)
| Active |
| US7579449
(Pediatric)
| Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Feb, 2029
(4 years from now)
| Active |
| US7579449 | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
01 Aug, 2028
(3 years from now)
| Active |
| US7713938
(Pediatric)
| Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Oct, 2027
(3 years from now)
| Active |
| US8673927 | Uses of DPP-IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US9173859 | Uses of DPP IV inhibitors |
04 May, 2027
(2 years from now)
| Active |
| US7713938 | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
15 Apr, 2027
(2 years from now)
| Active |
| US8883805
(Pediatric)
| Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 May, 2026
(1 year, 8 months from now)
| Active |
| US8883805 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
26 Nov, 2025
(1 year, 2 months from now)
| Active |
| US7407955
(Pediatric)
| 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 Nov, 2025
(1 year, 1 month from now)
| Active |
| US7407955 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
02 May, 2025
(7 months from now)
| Active |
| US8119648 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US8178541 | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
12 Aug, 2023
(1 year, 1 month ago)
| Expired |
| US6488962 | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
20 Jun, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Trijardy Xr's drug page
25. Twynsta
Twynsta is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5591762 | Benzimidazoles useful as angiotensin-11 antagonists |
07 Jan, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twynsta's drug page
26. Viramune Xr
Viramune Xr is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8460704 | Extended release formulation of nevirapine |
12 Mar, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Viramune Xr's drug page